19X Stock Overview A biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Axsome Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Axsome Therapeutics Historical stock prices Current Share Price US$84.22 52 Week High US$98.88 52 Week Low US$59.56 Beta 1.04 1 Month Change -8.81% 3 Month Change 8.06% 1 Year Change 13.32% 3 Year Change 193.65% 5 Year Change 9.38% Change since IPO 2,205.50%
Recent News & Updates
New minor risk - Share price stability Dec 31
Axsome Therapeutics, Inc. Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation Dec 30
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy Nov 26
New minor risk - Share price stability Nov 16
New minor risk - Shareholder dilution Nov 14
Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.32 loss in 3Q 2023) Nov 14 See more updates
New minor risk - Share price stability Dec 31
Axsome Therapeutics, Inc. Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation Dec 30
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy Nov 26
New minor risk - Share price stability Nov 16
New minor risk - Shareholder dilution Nov 14
Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.32 loss in 3Q 2023) Nov 14
Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 15
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine Sep 05
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc Aug 21
New minor risk - Share price stability Aug 07
Second quarter 2024 earnings released: US$1.67 loss per share (vs US$1.54 loss in 2Q 2023) Aug 06
Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 12
Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd Jun 06
Forecast breakeven date pushed back to 2026 May 07
First quarter 2024 earnings released: US$1.44 loss per share (vs US$0.26 loss in 1Q 2023) May 06
Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024 Apr 28
Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 11
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder Apr 02 Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder Mar 19
Full year 2023 earnings released: US$5.27 loss per share (vs US$4.60 loss in FY 2022) Feb 22
Forecast to breakeven in 2025 Feb 20
Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Jan 24
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers Nov 17
Forecast to breakeven in 2025 Nov 08
Third quarter 2023 earnings released: US$1.32 loss per share (vs US$1.08 loss in 3Q 2022) Nov 07
Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference Oct 25 Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors Oct 12
Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 13
Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults Jul 08 Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million. Jun 30
Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million. Jun 29
Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023 Jun 02
Forecast to breakeven in 2025 Apr 27
Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 01
Forecast to breakeven in 2025 Dec 31
Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting Dec 08
Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation Nov 29
Insufficient new directors Nov 16
Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 22
Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Oct 21
No longer forecast to breakeven Oct 20
Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Oct 04
Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting Sep 30
Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation Sep 09
Forecast to breakeven in 2024 Sep 08
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research Sep 08
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor Sep 02
Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Aug 20
No longer forecast to breakeven Aug 11
Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 29
Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration Jun 28
The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 12, 2022 Jun 09
Axsome Therapeutics Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs-05 on Anhedonia in Patients with Major Depressive Disorder Jun 04
Axsome Therapeutics, Inc. Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs 05 on Anhedonia in Patients with Major Depressive Disorder Jun 03 Axsome Therapeutics Announces Positive Results of the Evolve Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in the Journal of Clinical Psychiatry Jun 01
Axsome Therapeutics Announces Publication of Pivotal Ascend Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry May 19
Pomerantz Law Firm Announces the Filing of A Class Action Against Axsome Therapeutics, Inc. and Certain Officers May 14
No longer forecast to breakeven May 03
Insufficient new directors Apr 27 Axsome Therapeutics, Inc. to Report Q1, 2022 Results on May 02, 2022
Axsome Therapeutics, Inc., Annual General Meeting, Jun 03, 2022 Apr 23
Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million. Mar 29
Axsome Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 16
Axsome and Baudax Bio, Inc. Enters into Litigation Discontinuance Agreement Feb 08
Forecast to breakeven in 2024 Jan 01
Independent Lead Director recently bought €130k worth of stock Nov 24
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy Sep 19
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine Sep 15
Axsome Therapeutics, Inc. Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder Aug 24
No longer forecast to breakeven Aug 10
Axsome Therapeutics, Inc. Notifies the U.S. Food and Drug Administration Rescinding the Company’s Breakthrough Therapy Designation for Its AXS-12 Product Candidate for the Treatment of Cataplexy in Narcolepsy Jul 15
Axsome Therapeutics, Inc. Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia Jun 16
Axsome Therapeutics, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder Apr 27
New 90-day low: €56.14 Feb 23
Axsome Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 17
Axsome Therapeutics, Inc Announces Results from the Company's MOVEMENT trial of AXS-07 Jan 02 Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
New 90-day high: €69.76 Dec 24
Axsome Therapeutics, Inc. Announces Positive Results from the Comet-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation Dec 10
Axsome Therapeutics, Inc. Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression Dec 03
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder Dec 02
New 90-day low: €55.69 Nov 07
Axsome Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
New 90-day low: €57.79 Oct 22
Axsome Therapeutics, Inc. announced that it expects to receive $225 million in funding from Hercules Capital, Inc., and other investors Sep 30
Axsome Therapeutics, Inc. Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Sep 26
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting Sep 22
New 90-day low - €60.36 Sep 03
Axsome Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Jul 31
New 90-day low - €62.70 Jul 30 Shareholder Returns 19X DE Pharmaceuticals DE Market 7D 1.8% -0.2% -0.4% 1Y 13.3% -17.1% 7.9%
See full shareholder returns
Return vs Market: 19X exceeded the German Market which returned 7.9% over the past year.
Price Volatility Is 19X's price volatile compared to industry and market? 19X volatility 19X Average Weekly Movement 9.3% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 19X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 19X's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Show more Axsome Therapeutics, Inc. Fundamentals Summary How do Axsome Therapeutics's earnings and revenue compare to its market cap? 19X fundamental statistics Market cap €4.07b Earnings (TTM ) -€301.75m Revenue (TTM ) €328.44m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 19X income statement (TTM ) Revenue US$338.46m Cost of Revenue US$30.17m Gross Profit US$308.29m Other Expenses US$619.25m Earnings -US$310.95m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.42 Gross Margin 91.09% Net Profit Margin -91.87% Debt/Equity Ratio 193.8%
How did 19X perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 16:54 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Axsome Therapeutics, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joel Beatty Baird Esther Lannie Hong Berenberg Jason Matthew Gerberry BofA Global Research
Show 23 more analysts 
